

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 June 2006 (29.06.2006)

PCT

(10) International Publication Number
WO 2006/066747 A1

(51) International Patent Classification:

C07D 211/58 (2006.01) A61K 31/4468 (2006.01)
C07D 211/60 (2006.01) A61K 31/45 (2006.01)
C07D 277/04 (2006.01)

(21) International Application Number:

PCT/EP2005/013292

(22) International Filing Date:

12 December 2005 (12.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

04106711.7 20 December 2004 (20.12.2004) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstr. 124, CH-4070 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOEHRINGER, Markus** [CH/CH]; Dachsweg 4, CH-4313 Moehlin (CH). **HUNZIKER, Daniel** [CH/CH]; Buerklistrasse 14, CH-4313 Moehlin (CH). **KUHN, Bernd** [DE/CH]; Sonnmattweg 42, CH-4410 Liestal (CH). **LOEFFLER, Bernd, Michael** [DE/CH]; Industriestrasse 27, CH-6300 Zug (CH). **LUEBBERS, Thomas** [DE/DE]; Talweg 10a, 79540 Loerrach (DE). **RICKLIN, Fabienne** [FR/FR]; 6, Impasse des Cerisiers, F-68490 Hombourg (FR).

(74) Agent: **KLOSTERMEYER, Doerte**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-AMINOPIPERIDINE DERIVATIVES




(I)

(57) Abstract: The present invention relates to compounds of the formula (I), wherein R¹ and R² are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/ or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and/or impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection.

4-Aminopiperidine Derivatives

The present invention relates to novel 4-aminopiperidine derivatives, their manufacture and their use as medicaments.

In particular, the invention relates to compounds of the formula (I)



5

wherein

R^1 is selected from the group consisting of

phenyl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, lower alkoxy, phenyl, phenoxy, halogen, or lower halogenalkyl;

10 naphthyl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

tetrahydronaphthyl;

C_{3-7} -cycloalkyl;

15 $-(CHR^3)_m$ -phenyl, wherein m is 1, 2, or 3 and phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy, and wherein R^3 is independently selected from hydrogen, lower alkyl or phenyl;

$-(CH_2)_n$ -heteroaryl, wherein n is 1, 2 or 3;

20 $-(CH_2)_n$ -heteroaryl, wherein n is 1, 2, 3 and heteroaryl is mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy;

-C(O)-CH₂-phenyl, with phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

-C(O)-CH₂-heteroaryl; and

- 5 -C(O)-CH₂-heteroaryl, wherein heteroaryl is mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy; and

R² is selected from the group consisting of

lower alkyl, lower halogenalkyl;

- 10 phenyl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy;

naphthyl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy;

heteroaryl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy;

- 15 -COOH; ~

-C(O)-NR⁴R⁵; wherein

R⁴ and R⁵ are lower alkyl or together with the nitrogen atom to which they are attached form a 4-, 5- or 6- membered heterocycle which may contain a further heteroatom selected from O, N or S,

- 20 and pharmaceutically acceptable salts thereof.

The enzyme dipeptidyl peptidase IV EC.3.4.14.5 (EC is the abbreviation for "Enzyme Committee" of the International Union of biochemistry this enzyme is abbreviated in the following as DPP-IV) is involved in the regulation of the activities of several hormones. In particular DPP-IV is degrading efficiently and rapidly glucagon like peptide 1 (GLP-1), which is one of the most potent stimulator of insulin production and secretion. Inhibiting DPP-IV would potentate the effect of endogenous GLP-1, and lead to higher plasma insulin concentrations. In patients suffering from impaired glucose tolerance and type 2 diabetes mellitus, higher plasma insulin concentration would moderate the dangerous hyperglycemia and accordingly reduce the risk of tissue damage. Consequently, DPP-IV inhibitors have been suggested as drug candidates for the treatment of impaired glucose tolerance and type 2 diabetes mellitus (e.g. Villhauer,

25

30

WO98/19998). Other related state of the art can be found in WO 99/38501, DE 19616486, DE 19834591, WO 01/40180, WO 01/55105, US 6110949, WO 00/34241 and US6011155.

We have found novel DPP-IV inhibitors that very efficiently lower plasma glucose
5 levels. Consequently, the compounds of the present invention are useful for the
treatment and/or prophylaxis of diabetes, particularly non-insulin dependent diabetes
mellitus, and/or impaired glucose tolerance, as well as other conditions wherein the
amplification of action of a peptide normally inactivated by DPP-IV gives a therapeutic
benefit. In addition, the compounds of the present invention can also be used in the
10 treatment and/or prophylaxis of obesity, metabolic syndrome, β -cell protection,
autoimmune diseases such as inflammatory bowel disease, encephalitis periaxialis
scleroticans and rheumatoid arthritis, Colitis Ulcerosa, Morbus Crohn, psoriasis, lichen
planus and/or benign prostate hypertrophy. The compounds may also be useful for the
prevention of AIDS (acquired immunodeficiency syndrome) or for the preventing
15 metastasis, particularly preventing metastasis of breast and prostate cancer to lung.
Furthermore, the compounds of the present invention can be used as diuretic agent and
for the treatment and/or prophylaxis of hypertension.

Unexpectedly, the compounds of the present invention exhibit improved
therapeutic and pharmacological properties compared to other DPP-IV inhibitors
20 known in the art, such as e.g. in context of pharmacokinetics and bioavailability.

Objects of the present invention are compounds of formula I and their production,
as well as the use of the compounds of formula I in accordance with the invention in the
control and prevention of illnesses of the aforementioned kind, and respectively, for the
production of corresponding medicaments.

25 Unless otherwise indicated, the following definitions are set forth to illustrate and
define the meaning and scope of the various terms used to describe the invention herein.

In this specification the term "lower" is used to mean a group consisting of one to
six, preferably of one to four carbon atom(s).

The term "halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine
30 and chlorine being preferred. Most preferred halogen is chlorine.

The term "alkyl", alone or in combination with other groups, refers to a branched
or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty
carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten

carbon atoms. The term "lower alkyl" or "C₁₋₆-alkyl", alone or in combination with other groups, refers to a branched or straight-chain monovalent alkyl radical of one to six carbon atoms, preferably one to four carbon atoms. This term is further exemplified by radicals such as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, isobutyl, t-butyl, n-
5 pentyl, 3-methylbutyl, n-hexyl, 2-ethylbutyl and the like. Preferable lower alkyl residues are methyl ethyl, n-propyl and n-butyl, with methyl being especially preferred.

The term "lower halogenalkyl" refers to a lower alkyl group wherein at least one of the hydrogens of the lower alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Among the preferred lower halogenalkyl groups are
10 trifluoromethyl, difluoromethyl, fluoromethyl and chloromethyl, with trifluoromethyl being especially preferred.

The term "alkoxy" refers to the group R'-O-, wherein R' is alkyl. The term "lower alkoxy" refers to the group R'-O-, wherein R' is lower-alkyl. Examples of lower alkoxy groups are e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy and hexyloxy,
15 with methoxy being especially preferred.


The term "cycloalkyl" or "C₃₋₇-cycloalkyl" refers to a monovalent carbocyclic radical of three to seven carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, with cyclopropyl and cyclohexyl being preferred.

20 The term "heteroaryl" refers to an aromatic 5- or 6-membered ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur such as furyl, pyridyl, 1,2-, 1,3- and 1,4-diazinyl, thienyl, isoxazolyl, oxazolyl, imidazolyl, or pyrrolyl. The term "heteroaryl" further refers to bicyclic aromatic groups comprising two 5- or 6-membered rings, in which one or both rings can contain 1, 2 or 3 atoms selected from
25 nitrogen, oxygen or sulphur such as e.g. indole or quinoline, or partially hydrogenated bicyclic aromatic groups such as e.g. indolinyl. Preferred heteroaryl groups are thienyl, pyridyl and indolyl, which can optionally be substituted as described above, preferably with lower alkyl or halogen.

The term "R⁴ and R⁵ together with the nitrogen atom to which they are attached
30 form a 4-, 5-, or 6-membered heterocycle which may contain an additional heteroatom selected from O, N or S" means that R⁴ and R⁵ together with the nitrogen atom form a ring such as pyrrolidinyl, dihydropyrrolyl (pyrrolinyl), piperidyl, imidazolidinyl, morpholinyl, piperazinyl, thiazolidinyl, thiomorpholinyl, with thiazolidinyl and dihydropyrrolyl being especially preferred.

The term "pharmaceutically acceptable salts" embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, salicylic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts with acids are formates, maleates, citrates, hydrochlorides, hydrobromides and methanesulfonic acid salts, with hydrochlorides being especially preferred.

The invention relates to compounds of the formula (I)



wherein

R^1 is selected from the group consisting of

phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, lower alkoxy, phenyl, phenoxy, halogen or lower halogenalkyl;

naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

tetrahydronaphthyl;

C_{3-7} -cycloalkyl;

$-(CHR^3)_m$ -phenyl, wherein m is 1, 2, or 3 and phenyl being unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy and wherein R^3 is independently selected from hydrogen, lower alkyl or phenyl;

$-(CH_2)_n$ -heteroaryl, wherein n is 1, 2 or 3;

$-(CH_2)_n$ -heteroaryl, wherein n is 1, 2, 3 and heteroaryl is mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl or lower alkoxy;

-C(O)-CH₂-phenyl, with phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

-C(O)-CH₂-heteroaryl; and

- 5 -C(O)-CH₂-heteroaryl, wherein heteroaryl is mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy; and

R² is selected from the group consisting of

lower alkyl, lower halogenalkyl;

- 10 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

heteroaryl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

- 15 -COOH;

-C(O)-NR⁴R⁵; wherein

R⁴ and R⁵ are lower alkyl or together with the nitrogen atom to which they are attached form a 4-, 5- or 6- membered heterocycle which may contain a further heteroatom selected from O, N or S,

- 20 and pharmaceutically acceptable salts thereof.

In preferred compounds of the present invention, R¹ is selected from the group consisting of

phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

- 25 naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

-(CHR³)_m-phenyl, wherein m is 1 or 2 and with phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy and wherein R³ is hydrogen;

-(CH₂)_n-heteroaryl, wherein n is 1 or 2;

-(CH₂)_n-heteroaryl, wherein n is 1 or 2 and with heteroaryl mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

5 -C(O)-CH₂-phenyl, with phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

-C(O)-CH₂-heteroaryl; and

10 -C(O)-CH₂-heteroaryl, with heteroaryl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

One group of preferred compounds of formula I according to the present invention are those compounds, wherein R¹ is selected from the group consisting of

phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

15 naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy; and

-(CHR³)_m-phenyl, wherein m is 1 or 2 and with phenyl being unsubstituted or mono-, di, or trisubstituted by lower alkoxy and wherein R³ is hydrogen.

20 Especially preferred are compounds of formula I, wherein R¹ is

phenyl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy.

More preferably R¹ is phenyl di- or trisubstituted by lower alkoxy, with R¹ being 3,4-dimethoxyphenyl or 2,3,4-trimethoxyphenyl being most preferred.

25 A further group of preferred compounds of formula I are those, wherein R¹ is

-(CH₂)_n-heteroaryl, wherein n is 1 or 2; or

$-(CH_2)_n$ -heteroaryl, wherein n is 1 or 2 and with heteroaryl mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

Preferred heteroaryl is indolyl or pyridyl.

5 Preferred meaning of n is 2.

Also preferred are compounds of formula I, wherein R^1 is

$-C(O)-CH_2$ -phenyl, with phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy; or

10 $-C(O)-CH_2$ -heteroaryl.

Especially preferred are $-C(O)-CH_2$ -phenyl and $-C(O)-CH_2$ -thienyl.

In preferred compounds of the present invention, R^2 is selected from the group consisting of

lower alkyl;

15 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

heteroaryl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy; and

20 $-C(O)-NR^4R^5$, wherein R^4 and R^5 together with the nitrogen atom to which they are attached form a 5-membered heterocycle which may contain a further heteroatom selected from O, N or S.

Especially preferred are compounds of formula I, wherein R^2 is lower alkyl, with n-butyl being most preferred.

Another group of preferred compounds of formula I are those, wherein R^2 is

25 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

Especially preferred are those compounds of formula I, wherein R² is phenyl or phenyl mono-, di-, or trisubstituted, independently, by lower alkyl or halogen.

Also preferred are compounds of formula I, wherein R² is

heteroaryl, unsubstituted or mono-, di, or trisubstituted, independently, by lower
5 alkyl, halogen, lower halogenalkyl, or lower alkoxy, with compounds, wherein heteroaryl
is pyridyl or thienyl being especially preferred.

Further preferred are compounds of formula I, wherein R² is

-C(O)-NR⁴R⁵, wherein R⁴ and R⁵ together with the nitrogen atom to which they
are attached form a 5-membered heterocycle which may contain a further
10 heteroatom selected from O, N or S.

Especially preferred are compounds of formula I, wherein R² is

-C(O)-thiazolidinyl or -C(O)-dihydropyrrolyl.

Examples of compounds of the formula I of the present invention are the
following:

- 15 (cis)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
(trans)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
(cis)-3-butyl-1-benzyl-piperidine-4-yl-amine
(trans)-3-butyl-1-benzyl-piperidine-4-yl-amine
(cis)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine, (
20 (trans)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine,
(cis)-3-butyl-1-[2-(3,4-dimethoxy-phenyl-1yl)-ethyl] piperidine-4-ylamine,
(trans)-3-butyl-1-[2-(3,4-dimethoxy-phenyl-1yl)-ethyl] piperidine-4-ylamine,
(cis)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(trans)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
25 (cis)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,

- (*trans*)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,
- (*cis/trans*)-3-butyl-1-(5,6,7,8-tetrahydro-naphthalen-1-yl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3, 4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- 5 (*trans*)-3-butyl-1-(3, 4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-naphthalen-1-yl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3, 4-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- 10 (*cis*)-3-butyl-1-(4-chloro-3-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- 15 (*cis/trans*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- 20 (*cis/trans*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-cyclohexyl-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-(3,5-bis-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- 25 (*cis*)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,

- (*trans*)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-3-butyl-1-benzhydryl-4-yl-piperidine-4-yl-amine hydrochloride,
(*cis*)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,
(*trans*)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,
5 (*cis*)-3-phenyl-1-benzyl-piperidine-4-yl-amine,
(*trans*)-3-phenyl-1-benzyl-piperidine-4-yl-amine,
(*cis/trans*)-methyl-1'-phenethyl-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-amine,
(*cis*)-3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,
(*cis/trans*)-3-(3-chloro-phenyl)-1-benzyl-piperidine-4-yl-amine,
10 (*cis/trans*)-3-(3-methyl-phenyl)-1-benzyl-piperidine-4-yl-amine,
(*cis*)-3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-yl-amine,
(*trans*)-1-benzyl-3-thiophen-2-yl-piperidine-4-yl amine
(*cis*)-3-o-tolyl-1-(3, 4, 5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(*trans*)-3-o-tolyl-1-(3, 4, 5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
15 (*cis/trans*)-3-o-tolyl-1-(3, 4, 5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-p-tolyl-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-(3, 4-dimethyl-phenyl)-piperidine-4-yl-amine
hydrochloride,
20 (*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-(3-methoxy-phenyl)-piperidine-4-yl-amine
hydrochloride,
(*cis/trans*)-1'-(3,4-dimethoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-
amine,
((3R,4S)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
25 ((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,

- [(3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone,
- 1-[(3S, 4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone,
- 1-[(3S-4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-thiophen-2-yl-ethanone,
- 3-[(3S,4R) and (3R,4S)-4-amino-1-[2(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid,
- 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone
- 10 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone,
- 3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone, and
- pharmaceutically acceptable salts thereof.
- 15 Preferred compounds of formula I are selected from:
- (*cis*)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
- (*cis*)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine,
- (*cis*)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,
- 20 (*cis*)-3-butyl-1-(3,4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-naphthalen-1-yl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3,4-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- 25 (*cis*)-3-butyl-1-(4-chloro-3-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,

- (*cis*)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
- 5 (*cis*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,
- 10 (*cis*)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,
- (*cis/trans*)-methyl-1'-phenethyl-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-amine,
- (*cis*)-3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,
- (*cis/trans*)-3-(3-chloro-phenyl)-1-benzyl-piperidine-4-yl-amine,
- (*cis/trans*)-3-(3-methyl-phenyl)-1-benzyl-piperidine-4-yl-amine,
- 15 (*cis*)-3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-yl-amine,
- (*trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-1'-(3,4-dimethoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-
- 20 amine,
- ((3R,4S)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
- ((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
- [(3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone,
- 25 1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone,


- 1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-thiophen-2-yl-ethanone,
- 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone
- 5 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone,
- 3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone, and
- pharmaceutically acceptable salts thereof.
- 10 Most preferred compounds are selected from
- 3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,
- 3-(3-chloro-phenyl)-1-benzyl-piperidine-4-ylamine,
- 3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-ylamine,
- 1-(3,4-dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl amine hydrochlorid,
- 15 ((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
- [(3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone,
- 3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone,
- 20 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone, and
- pharmaceutically acceptable salts thereof.

The compounds of formula I have two asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of diastereomers, racemates, or


25 mixtures of diastereoisomeric racemates. The invention embraces all of these forms.

In a preferred embodiment, R² and the amino group of the piperidine structure are in *trans*-configuration, i.e.

- 15 -




In a further preferable embodiment, R^2 and the amino group of the piperidine structure are in *cis*-configuration, i.e.




- 5 In a further embodiment the invention comprises a process for the manufacture of compounds of formula I, which process comprises

either

- a) converting a compound of the formula



- 10 wherein R^1 and R^2 are as defined before,
with hydroxylamine or a salt thereof into an oxime of the formula




wherein R^1 and R^2 are as defined before,

- 16 -

and further reducing the oxime of formula III by catalytic hydrogenation or alternatively by a reduction with a metal hydride into the compound of formula I

or

b) deprotecting an 4-aminopiperidine derivative of the formula



5

wherein R^1 and R^2 are as defined before and R^P is an amino protecting group.


R^P is a suitable amino protecting group such as benzyloxycarbonyl (Z or Cbz), allyloxycarbonyl (Aloc), 9-fluorenylmethoxycarbonyl (Fmoc), and preferably, tert-butoxycarbonyl (Boc).

10 In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods shown in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to the person skilled in the art. Starting materials are commercially available or can be prepared by methods analogous to the method given below or in the examples or by methods
15 known in the art.

The compounds of formula I of the present invention can be prepared as indicated in schemes 1 to 6 below:

4-Aminopiperidines of the formula I with R^1 having the meaning of $-(CHR^3)_m$ -phenyl and $-(CH_2)_n$ -heteroaryl, wherein R^3 , n and m are as defined above and R^2 being
20 lower alkyl can be prepared following scheme 1:


Scheme 1



In a first step, R^2 with the meaning of lower alkyl is inserted in 3-position via a
 5 transformation of a N-protected 4-oxo-piperidine carboxylic acid alkyl ester (Alk =
 lower alkyl) with a suitable alkyl iodide. N-protection can easily be achieved with a
 benzyl group (Bz). In a second step, the N-protection is removed e.g. by a catalytic
 hydrogenation, and subsequently in a third step, an R^1 -halogenide with R^1 having the
 meaning of $-(\text{CHR}^3)_m$ -phenyl and $-(\text{CH}_2)_n$ -heteroaryl is reacted with the deprotected
 10 piperidine to the respective 3-alkyl-1-aryl-4-oxo-piperidine. In case R^1 is benzyl, these
 two last steps can be omitted. Transformation of the 3-alkyl-1-aryl-4-oxo-piperidine into
 the desired 4-aminopiperidine can then take place via an oxime formation with
 hydroxylamine followed by a reduction for example by LiAlH_4 (LAH) in a suitable
 solvent.

15 4-Aminopiperidines of the formula I with R^1 having the meaning of unsubstituted
 or mono-, di, or trisubstituted phenyl, unsubstituted or mono-, di, or trisubstituted
 naphthyl, tetrahydronaphthyl or C_{3-7} -cycloalkyl and R^2 being lower alkyl can be prepared
 following scheme 2:


Scheme 2



In a first step, a 4-oxo-piperidinium iodide can be formed from a suitably N-benzyl protected 3-alkyl-4-oxo-piperidine per reaction with methyl iodide in a suitable solvent. R^1 can be inserted by reaction of the 4-oxo-piperidinium iodide with the respective aniline R^1NH_2 thereby forming the respective 3-alkyl-1-aryl-4-oxo-piperidine. Transformation of this intermediate into the desired 4-aminopiperidine can then take place via an oxime formation with hydroxylamine followed by a reduction for example by catalytic hydrogenation in the presence of a common hydrogenation catalyst such as Raney Nickel or palladium/charcoal in a suitable solvent.

4-Aminopiperidines of the formula I with R^1 having the meaning of $-(\text{CHR}^3)_m$ -phenyl and $-(\text{CH}_2)_n$ -heteroaryl, wherein R^3 , n and m are as above and R^2 being unsubstituted or mono-, di, or trisubstituted phenyl, unsubstituted or mono-, di, or trisubstituted naphthyl or unsubstituted or mono-, di, or trisubstituted heteroaryl can be prepared following scheme 3:


Scheme 3



In a first reaction sequence an acrylic acid ester is reacted with the respective arylalkylamine R^1NH_2 to form the respective arylalkylamino propionic acid ester which is then converted with the respective arylacetic acid or aryl acetic acid halogenide R^2COOH or R^2COHal into an R^2 acetyl amino propionic acid ester. Subsequent ring formation with e.g. an alkalibutylate or with sodium hydride leads to a piperidine-2,4-dione which is then transformed with hydroxylamine to the piperidine-2,4-dione-4-oxime. This intermediate can finally be reduced for example with $LiAlH_4$ (LAH) in a suitable solvent to the desired 4-aminopiperidine.

4-aminopiperidines of the formula I with R^1 having the meaning of unsubstituted or mono-, di, or trisubstituted phenyl, unsubstituted or mono-, di-, or trisubstituted naphthyl, tetrahydronaphthyl or C_{3-7} -cycloalkyl and R^2 being unsubstituted or mono-, di-, or trisubstituted phenyl, unsubstituted or mono-, di, or trisubstituted naphthyl or unsubstituted or mono-, di, or trisubstituted heteroaryl can be prepared following scheme 4:

15 Scheme 4




The synthesis of 1-aryl-3-aryl-4-amino piperidines can either be performed following scheme 2 via an N-benzyl-protected 3-aryl-4-oxo-piperidinium iodide which is treated with the aniline R^1NH_2 to give the respective 3-aryl-1-aryl-4-oxo-piperidine. Treatment of this compound with hydroxylamine will give the corresponding oxime that can be reduced subsequently to give the desired 4-amino-piperidine.

As an alternative an N-benzyl-protected 4-oxo-piperidinium iodide can be reacted in a first step with aryl aniline R^1NH_2 to give the 1-aryl-4-oxo-piperidine. The aryl-group in position 3 can then be introduced with an aryl halogenide R^2Hal in the presence of

Pd-acetate, sodium tert-butoxide and $P(tBu)_3$. The resulting 3-aryl-1-aryl-4-oxo-piperidine can then be transformed to the desired 4-amino piperidine as outlined above.

- 4-aminopiperidines of the formula I with R^1 having the meaning of $-(CHR^3)_m$ -phenyl and $-(CH_2)_n$ -heteroaryl, wherein R^3 , n and m are as above and R^2 being $-C(O)-NR^4R^5$, wherein R^4 and R^5 are as above can be prepared following scheme 5:

Scheme 5




- In a first step the amino group of a 4-amino-piperidine-1,3-dicarboxylic acid di-ester is protected with a benzyloxycarbonyl group. The ester group in position 3 can then be hydrolyzed, followed by formation of the amide using the corresponding amine HNR^4R^5 under standard peptide coupling conditions. In the subsequent steps, the BOC protecting group at position 1 can be removed for example by treatment with trifluoroacetic acid and then the arylalkyl group can be introduced at N1 by treatment with the respective aryl alkyl halogenide $R^1 Hal$. Finally the desired 4-aminopiperidine

can be obtained by removal of the benzyloxycarbonyl protecting group in the presence of HBr.

4-aminopiperidines of the formula I with R^1 having the meaning of unsubstituted or mono-, di, or trisubstituted phenyl, unsubstituted or mono-, di-, or trisubstituted naphthyl, tetrahydronaphthyl or C_{3-7} -cycloalkyl and R^2 being unsubstituted or mono-, di, or trisubstituted phenyl, unsubstituted or mono-, di, or trisubstituted naphthyl or unsubstituted or mono-, di, or trisubstituted heteroaryl can be prepared following scheme 6:

Scheme 6




10

A 1-benzyl-4-oxo-piperidine-3-carboxylic acid ester is first reacted with ammonia to give the respective tetrahydropyridine which can then be reduced for example with sodium borohydride to give the 4-amino piperidine carboxylic acid ester. BOC protection of the amino group in 4-position and subsequent removal of the benzyl group by e.g. catalytic hydrogenation in the presence of a hydrogenation catalyst then affords 4-N-BOC protected piperidine-3-carboxylic acid ester. The arylalkyl group R^1 can be inserted using the respective aldehyde $R^1CH=O$ followed by reduction. Removal of the BOC protecting group and ester hydrolysis with a suitable alkali hydroxide leads to the desired 1-arylalkyl-4-amino piperidine-3-carboxylic acid.

4-aminopiperidines of the formula I with R^1 having the meaning of $-(CHR^3)_m$ -phenyl and $-(CH_2)_n$ -heteroaryl, wherein R^3 , n and m are as above and R^2 being $-C(O)-NR^4R^5$, wherein R^4 and R^5 are as above can be prepared following scheme 7:

20

Scheme 7



In a first reaction sequence an arylamine R^1 is reacted with an acrylic acid ester in the presence of $CuCl$ and acetic acid to form the respective 1-aryl-4-oxo-piperidine-3-carboxylic acid ester. Treatment of this intermediate with ammonium acetate and sodium cyano borohydride gives the 1-aryl-4-amino piperidine-3-carboxylic acid ester. BOC protection of the free amino group in 4-position and subsequent ester hydrolysis provides the free carboxylic acid which can then be used for coupling with amine R^4R^5NH . The desired 4-aminopiperidine can then be obtained by removal of the BOC protecting group with e.g. trifluoro acetic acid.

The invention further relates to compounds of formula I as defined above, when manufactured according to a process as defined above.

The invention also relates to compounds of formula I as defined above for use as therapeutic active substances for the treatment and / or prophylaxis of diseases which are associated with DPP-IV.

Such diseases which are associated with DPP-IV are diabetes, particularly non-insulin dependent diabetes mellitus, and/or impaired glucose tolerance, as well as other conditions wherein the amplification of action of a peptide normally inactivated by DPP-IV gives a therapeutic benefit. In addition, the compounds of the present invention can also be used in the treatment and/or prophylaxis of obesity, metabolic syndrome, β -cell protection autoimmune diseases such as inflammatory bowel disease, encephalitis periaxialis scleroticans and rheumatoid arthritis, Colitis Ulcerosa, Morbus Crohn, psoriasis, lichen planus and/or benign prostate hypertrophy. The compounds may also be useful for the prevention of AIDS (acquired immunodeficiency syndrome) or for the preventing metastasis, particularly preventing metastasis of breast and prostate cancer to

lung. Furthermore, the compounds of the present invention can be used as diuretic agent and for the treatment and/or prophylaxis of hypertension.

As described above, the compounds of formula I of the present invention can be used as medicaments for the treatment and/or prophylaxis of such diseases which are
5 associated with DPP-IV as defined above.

The invention therefore also relates to pharmaceutical compositions comprising a compound formula I of the present invention and a pharmaceutically acceptable carrier and/or adjuvant.

Further the invention relates to compounds of formula I of the present invention
10 for use as therapeutic active substances, particularly as therapeutic active substances for the treatment and/or prophylaxis of the diseases which are associated with DPP-IV as defined above.

In another embodiment, the invention relates to a method for the treatment and/or prophylaxis of diseases which are associated with DPP-IV as defined above, which
15 method comprises administering a compound of formula I to a human being or animal.

The invention further relates to the use of compounds formula I of the present invention for the treatment and/or prophylaxis of diseases which are associated with DPP-IV as defined above.

In context with the methods and uses defined above, the following diseases relate
20 to a preferred embodiment: diabetes, particularly non-insulin dependent diabetes mellitus, impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection, preferably non-insulin dependent diabetes mellitus and/or impaired glucose tolerance.

The following tests were carried out in order to determine the activity of the
25 compound of formula I.

Activity of DPP-IV inhibitors are tested with natural human DPP-IV derived from a human plasma pool or with recombinant human DPP-IV. Human citrate plasma from different donors is pooled, filtered through a 0.2 micron membrane under sterile conditions and aliquots of 1 ml are shock frozen and stored at -120°C . In the
30 colorimetric DPP-IV assay 5 to 10 μl human plasma and in the fluorometric assay 1.0 μl of human plasma in a total assay volume of 100 μl is used as an enzyme source. The cDNA of the human DPP-IV sequence of amino acid 31-to 766, restricted for the N-terminus and the transmembrane domain, is cloned into *Pichia pastoris*. Human DPP-

IV is expressed and purified from the culture medium using conventional column chromatography including size exclusion and anion and cation chromatography. The final enzyme preparation was observed on SDS-page stained with Coomassie blue and shown a purity of > 95%. In the colorimetric DPP-IV assay 20 ng rec.h DPP-IV and in
5 the fluorometric assay 2 ng rec-h DPP-IV in a total assay volume of 100 μ l is used as enzyme source.

In the fluorogenic assay Ala-Pro-7-amido-4-trifluoromethylcoumarin (Calbiochem No 125510) is used as a substrate. A 20 mM stock solution in 10 % DMF/H₂O is stored at -20°C until use. In IC₅₀ determinations a final substrate
10 concentration of 50 μ M is used. In assays to determine kinetic parameters as K_m , V_{max} , K_i , the substrate concentration is varied between 10 μ M and 500 μ M.

In the colorimetric assay H-Ala-Pro-pNA·HCl (Bachem L-1115) is used as a substrate. A 10 mM stock solution in 10% MeOH/H₂O is stored at -20°C until use. In IC₅₀ determinations a final substrate concentration of 200 μ M is used. In assays to
15 determine kinetic parameters as K_m , V_{max} , K_i , the substrate concentration is varied between 100 μ M and 2000 μ M.

Fluorescence is detected in a Perkin Elmer Luminescence Spectrometer LS 50B at an excitation wavelength of 400 nm and an emission wavelength of 505 nm continuously every 15 seconds for 10 to 30 minutes. Initial rate constants are calculated by best fit
20 linear regression.

The absorption of pNA liberated from the colorimetric substrate is detected in a Packard Spectra Count at 405 nm continuously every 2 minutes for 30 to 120 minutes. Initial rate constants are calculated by best fit linear regression.

DPP-IV activity assays are performed in 96 well plates at 37°C in a total assay
25 volume of 100 μ l. The assay buffer consists of 50 mM Tris/HCl pH 7.8 containing 0.1 mg/ml BSA and 100 mM NaCl. Test compounds are solved in 100 % DMSO, diluted to the desired concentration in 10% DMSO/H₂O. The final DMSO concentration in the assay is 1 % (v/v). At this concentration enzyme inactivation by DMSO is < 5%.
Compounds are with (10 minutes at 37°C) and without pre-incubation with the enzyme.
30 Enzyme reactions are started with substrate application followed by immediate mixing.

IC₅₀ determinations of test compounds are calculated by non-linear best fit regression of the DPP-IV inhibition of at least 5 different compound concentrations. Kinetic parameters of the enzyme reaction are calculated at least 5 different substrate concentrations and at least 5 different test compound concentrations.

The compounds of the present invention exhibit IC₅₀ values of 0.1 μ M to 100 μ M, more preferably of 0.1 μ M to 10 μ M, as shown in the following table:

Example	IC ₅₀ [μ M]
23	0.16
29	0.59
36	0.29
40	0.82

The compounds of formula I and/or their pharmaceutically acceptable salts can be
5 used as medicaments, e.g. in the form of pharmaceutical preparations for enteral,
parenteral or topical administration. They can be administered, for example, perorally,
e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules,
solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories,
parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g.
10 in the form of ointments, creams or oils. Oral administration is preferred.

The production of the pharmaceutical preparations can be effected in a manner
which will be familiar to any person skilled in the art by bringing the described
compounds of formula I and/or their pharmaceutically acceptable salts, optionally in
combination with other therapeutically valuable substances, into a galenical
15 administration form together with suitable, non-toxic, inert, therapeutically compatible
solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic
carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc,
stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées
20 and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for
example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the
nature of the active ingredient no carriers might, however, be required in the case of soft
gelatine capsules). Suitable carrier materials for the production of solutions and syrups
are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier
25 materials for injection solutions are, for example, water, alcohols, polyols, glycerol and
vegetable oils. Suitable carrier materials for suppositories are, for example, natural or
hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for

topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.

Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-
5 improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and
10 the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 1000 mg, especially about 1 to 100 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.

15 The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-100 mg, of a compound of formula I.

The following Examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.

Examples

20 Abbreviations used:

DCM: dichloromethane; HOAc: acetic acid; AcOEt: ethyl acetate; DMF: dimethylformamide; DIPEA: diisopropylethylamine (Huenig's base); THF: tetrahydrofuran; LAH: lithium aluminium hydride; CDI: carbonyldiimidazole; TFA: trifluoro acetic acid; EDCl: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide HCl;
25 HOBt: 1-hydroxybenzotriazole.

RT: room temperature; HV: high vacuum. TLC: thin layer chromatography.

Example 1

3-Butyl-1-phenethyl-piperidine-4-yl-amine

Step A]: 1-Benzyl-3-butyl-piperidine-4-one

To a suspension of anhydrous potassium carbonate (22.8g) and 1-benzyl-4-oxo-
5 piperidine-3-carboxylic acid ethyl ester (10g) in acetone (125 ml) was added a solution
of butyl iodide (13.4g, 8.3 ml) in acetone (50 ml) under argon over a period of 30
minutes. The resulting suspension was stirred at RT for 30 min and then refluxed for 12
hours. The suspension was cooled, filtered and concentrated *in vacuo*. The residue was
dissolved in DCM and the solution was washed with water and brine, dried over Na₂SO₄
10 and evaporated. To the residue was added aqueous HCl (20%, 100 ml) and the solution
was refluxed for 24 hours. The solution was evaporated and the residue was dissolved in
DCM, washed with 10% aq. Na₂CO₃ solution and brine, dried and evaporated. The
crude product was purified by flash chromatography (ethyl acetate/hexanes 1:2) to give
the product as a slightly yellow oil (6.4 g). MS (ESI): 246.4 (MH⁺).

15 Step B]: 3-Butyl-piperidine-4-one

To a solution of 1-benzyl-3-butyl-piperidine-4-one (1.3 g) in HOAc/water 3:1 (25
ml) was added 10% Pd on charcoal (130 mg). A hydrogen atmosphere was introduced by
repeated evacuation/gas introduction. The suspension was vigorously stirred for 5 hours.
The catalyst was removed by filtration through dicalite and the filtrate was concentrated
20 *in vacuo*. The oily residue was treated with 10% aq. Na₂CO₃ and then extracted into
DCM. The organic layer was separated, dried over Na₂SO₄, filtered and evaporated to
give the crude product as slightly yellow oil (680 mg) which was used without further
purification. MS (ESI): 156.2 (MH⁺).

Step C]: 3-Butyl-1-phenethyl-piperidine-4-one

25 To a solution of 3-Butyl-piperidine-4-one (250 mg) in DMF (5 ml) was added
DIPEA (468 mg) and then a solution of (2-bromoethyl)-benzene (373 mg) in DMF (5
ml) over a period of 45 min. The resulting mixture was stirred at RT for 1 hour and then
heated to 60 °C for 6 hours. The reaction mixture was cooled, diluted with ether and the
organic solution was washed with 10% aq. Na₂CO₃ solution twice and brine. The organic
30 layer was dried over MgSO₄, filtered and evaporated to give a residue which was purified
by flash chromatography (ethyl acetate/hexanes 1:3) to give the product as a colorless
liquid (355 mg). MS (ESI): 260.4 (MH⁺).

- 28 -

Step D]: 3-Butyl-1-phenethyl-piperidine-4-one oxime

3-Butyl-1-phenethyl-piperidine-4-one (300 mg), NaOAc (878 mg) and hydroxylamine hydrochloride (708 mg) were suspended in ethanol/water (1:1, 10 ml) and the mixture was heated to reflux for 5 hours. The clear solution that resulted from this treatment was cooled, diluted with water and basified with 10% aq. Na₂CO₃ to pH 10. The suspension was extracted with DCM and the organic layer was washed with brine, dried (MgSO₄) and evaporated. The product was sufficiently pure for the next step. Yellowish glass, mixture of *cis* and *trans* diastereomers (332 mg). MS (ESI): 261.4 (MH⁺).

10 Step E] 3-Butyl-1-phenethyl-piperidine-4-ylamine

3-Butyl-1-phenethyl-piperidine-4-one oxime (218 mg) was dissolved in THF (10 ml) and LAH (261 mg) was added in one portion. The suspension was then allowed to stir at RT for 24 hours. The reaction mixture was carefully pipetted onto 5% aq. NaHCO₃ solution and the aqueous layer was extracted with DCM. The organic layer was washed with brine, dried (MgSO₄) and evaporated to give a colorless oil. This was purified by flash chromatography (gradient of MeOH in DCM containing 1% NH₄OH) to give the product as *cis* and *trans* diastereomers (*cis*: 127 mg; *trans*: 36 mg). MS (ESI): 261.4 (MH⁺).

Example 2

20 3-Butyl-1-benzyl-piperidine-4-yl-amine

This compound was synthesized in analogy to example 1, with the exception that Steps B] and C] were omitted altogether and the benzyl group was carried through the whole synthesis. *Cis* and *trans* diastereomers as colorless oils. MS (ESI): 247.4 (MH⁺).

Example 3

25 3-Butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine

This compound was synthesized as described in example 1 from 1-benzyl-4-oxo-piperidine-3-carboxylic acid ethyl ester and 3-(2-bromo-ethyl)-1H-indole as the alkylating agent in Step C]. *Cis* and *trans* diastereomers as colorless oils. MS (ESI): 300.5 (MH⁺).

Example 4

3-Butyl-1-[2-(3,4-dimethoxy-phenyl-1-yl)-ethyl]-piperidine-4-ylamine

This compound was synthesized as described in example 1 from 1-benzyl-4-oxo-piperidine-3-carboxylic acid ethyl ester and (2-bromoethyl)-3,4-dimethoxybenzene as
5 the alkylating agent used in Step C]. *Cis* and *trans* diastereomers as colorless oils. MS (ESI): 321.4 (MH⁺).

Example 5

3-Butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride

Step A]: 1-Benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide

10 To a solution of 3-butyl-1-benzyl-piperidine-4-one (9080 mg) in acetone (40 ml) was slowly added methyl iodide (6303 mg) at room temperature. The solution was stirred at room temperature for three hours. A white solid precipitated and was filtered off. The solid was washed four times with 50 ml of acetone and dried under reduced pressure. The filtrate was evaporated and the residue was stirred with ethyl acetate. The
15 white solid was filtered, washed with ethyl acetate and dried under vacuum. The two solids were combined to yield 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide as a white powder (11200 mg). MS (ESI): 204.2 (M-I⁻).

Step B]: 3-Butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-one

A slurry of 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide (306 mg) in
20 water (2 ml) was added in one portion to a refluxing solution of 3,4,5-trimethoxy aniline (929 mg) and anhydrous potassium carbonate (33 mg) in ethanol (4 ml). The dark solution was heated to reflux for three hours. Water was added and the reaction was extracted twice with DCM. The combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated to leave a dark oil, which was purified by flash
25 chromatography (ethyl acetate/hexanes 1:1) to give the product as a colorless oil (520 mg). MS (ESI): 322.4 (MH⁺).

Step C]: 3-Butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride

The ketone (460 mg) was dissolved in ethanol (60 ml). Hydroxylamine
30 hydrochloride (109 mg) and sodium acetate (129 mg) were added and the solution was stirred at room temperature for one hour. After TLC control, Raney-Nickel was added (Nr 313 Degussa B1132) and the reaction was stirred at room temperature under an

atmosphere of hydrogen over night. The catalyst was filtered off and the filtrate was concentrated. The residue was purified by chromatography on silica gel (DCM/ MeOH/ 25% aqueous NH₄OH solution 95:5:1). The separated products were dissolved in ethanol and 1 ml of saturated ethanolic hydrogen chloride solution was added. The solutions
5 were evaporated to yield the *cis*- (150 mg) and the *trans*-diastereomers (160 mg) as light yellow solids. MS (ESI): 323.4 (MH⁺).

Example 6

3-Butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 5 using Steps B] and C]
10 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 4-phenoxy-aniline with the exception that Step C] was replaced by a different method.

Step C (modified version)]: 3-Butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine hydrochloride

3-Butyl-1-(4-phenoxy-phenyl)-piperidine-4-one (320 mg) was dissolved in
15 ethanol (8 ml). Hydroxylamine hydrochloride (76 mg) and sodium acetate (89 mg) were added. The reaction turned yellow and the solution was stirred at room temperature for two hours. TLC control indicated the formation of the E/Z-oximes. Water (8 ml) was added. A suspension was obtained to which Al-Ni-alloy (300 mg) was added. 32 % aqueous sodium hydroxide solution (1.4 ml) was added slowly. The reaction turned
20 warm. After complete addition, the reaction was stirred for two hours at room temperature and the solid was filtered off. The precipitate was washed with DCM. The aqueous solution was extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH/aq. sat. NH₄OH solution
25 100:5:1). The separated products were dissolved in ethanol and 1 ml of saturated ethanolic hydrogen chloride solution was added. The solutions were evaporated to yield the *cis*- (117 mg) and the *trans*-diastereomer (52 mg) as light yellow solids. MS (ESI): 325.5 (MH⁺) *trans* and *cis*.

Example 7

30 3-Butyl-1-(5,6,7,8-tetrahydro-naphthalen-1-yl)-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 5-amino-tetraline to yield a mixture of *cis*- and

trans-diastereomers as a white solid. Separation of the diastereomers (as the free amines) using flash chromatography was not possible. MS (ESI): 287.3 (MH^+).

Example 8

3-Butyl-1-(3,4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride

5 This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 3,4-dimethoxy-aniline to yield the *cis*- and the *trans*-diastereomers as white solids. MS (ESI): 293.4 (MH^+) *cis*- and *trans*-diastereomer.

Example 9

3-Butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride

10 This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 2-naphthyl-amine to yield a 5/2-mixture of the *cis*- and *trans*-diastereomers and the pure *trans*-diastereomer as white solids. MS (ESI): 283.2 (MH^+) *cis*- and *trans*-diastereomer.

Example 10

15 3-Butyl-1-naphthalen-1-yl-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 1-naphthylamine to yield a 1/2-mixture of the *cis*/*trans*-diastereomers as a white solid. Separation of the diastereomers (as the free amines) using flash chromatography was not possible. MS (ESI): 283.2 (MH^+).

20 Example 11

3-Butyl-1-(3,4-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 3,4-dichloro-aniline to yield the *cis*-diastereomer as a white solid. MS (ESI): 301.3 (MH^+).

25 Example 12

3-Butyl-1-(4-chloro-3-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 4-chloro-3-trifluoromethyl-aniline to yield the

cis-diastereomer and a 1/1-mixture of the *cis*- and *trans*-diastereomers as white solids.
MS (ESI): 335.3 (MH^+) *cis*- and *trans*-diastereomer.

Example 13

3-Butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride

5 This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 4-methyl-aniline to yield the *cis*- and *trans*-diastereomers as white solids. MS (ESI): 247.4 (MH^+).

Example 14

10 3-Butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride and 3-butyl-1-phenyl-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 3,5-dichloro-4-methyl-aniline to yield the *cis*- and a 1/1-mixture of the *cis*- and *trans*-diastereomers as white solids. MS (ESI): 301.3 (MH^+).

15 Overreduction led to the formation of the dehalogenated *cis*- and *trans*-phenyl derivatives, which were separated as the amines during flash chromatography. The hydrochlorides of the *cis*- and *trans*-diastereomers were isolated as white solids. MS (ESI): 233.3 (MH^+).

Example 15

20 3-Butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 3-methoxy-5-trifluoromethyl-aniline to yield a mixture of *cis*- and *trans*-diastereomers and the *cis*-diastereomer as white solids. MS (ESI): 331.4 (MH^+).

25 Example 16

3-Butyl-1-cyclohexyl-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and cyclohexyl amine to yield a mixture of *cis*- and *trans*-diastereomers as a white solid. ^1H NMR (DMSO): δ 2.81 – 2.65 (m, 2H), 2.60 – 2.00 (m, 5H), 1.74 – 1.60 (m, 5H), 1.60 – 1.40 (m, 3H), 1.40 – 1.00 (10 H), 0.87 (t, 3H).

30

Example 17

1-(3,5-Bis-trifluoromethyl-phenyl)-3-butyl-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 3,5-bis (trifluoromethyl)-aniline to yield a mixture of *cis*- and *trans*-diastereomers as a white solid. MS (ESI): 369.3 (MH⁺).

Example 18

3-Butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride

This compound was synthesized in analogy to example 6 from 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and 6-methoxy-biphenyl-3-ylamine to yield the *cis*- and the *trans*-diastereomers as white solids. ¹H NMR (DMSO, *cis*-diastereomer):
10 δ 7.47 (d, 2H), 7.38 (t, 2H), 7.32 (t, 1H), 6.97 (d, 1H), 6.89 (d, 1H), 6.82 (s, 1H), 3.67 (s, 3H), 3.07 (dd, 2H), 2.98 (m, 2H), 2.86 (dd, 1H), 1.62 (m, 3H), 1.29 (m, 6H), 0.88 (t, 3H).
¹H NMR (DMSO, *trans*-diastereomer): δ 7.47 – 7.20 (m, 8H), 3.62 (s, 3H), 3.54 (br d, 2H), 2.64 (m, 2H), 2.36 (m, 1H), 1.79 (m, 3H), 1.33 (m, 6H), 0.88 (t, 3H).

Example 19

1-Benzhydryl-3-butyl-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 6 from (rac)-1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide and diphenyl methyl amine to yield a 1/1-mixture of *cis*/*trans*-diastereomers as a white solid. ¹H NMR (DMSO): δ 7.37 (m, 4H),
20 7.27 (m, 4H), 7.16 (t, 2H), 4.26 & 4.22 (2s, 1H), 2.81 – 2.73 (m, 3H), 2.48 – 2.08 (m, 3H), 1.56 – 1.05 (m, 8H), 0.84 & 0.77 (2t, 3H).

Example 20

3-Phenyl-1-phenethyl-piperidine-4-yl-amine]

Step A]: 3-Phenethylamino-propionic acid ethyl ester

25 Phenylethyl amine (10 g) was dissolved in EtOH (50 ml) and then treated with acrylic acid ethyl ester (8.3 g) dropwise under argon at RT. The resulting mixture was allowed to stir over night and was evaporated and dried *in vacuo*. The residue (18.9 g) was used without further purification. Colorless liquid, MS (ESI): 222.3 (MH⁺).

Step B]: 3-(Phenethyl-phenylacetyl-amino)-propionic acid ethyl ester

3-Phenethylamino-propionic acid ethyl ester (8.0 g) was dissolved in absolute pyridine (12 ml) and cooled to 0 °C by means of an ice bath. Phenylacetic acid chloride (1.5 ml) was then added dropwise over a period of 10 min; a yellow suspension was
5 obtained. The mixture was then heated to 60 °C for 2.5 hours, cooled to RT and then allowed to stir over night. The mixture was poured into ice/water containing 25% HCl and the aqueous layer was extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over Na₂SO₄ and evaporated. The residue was purified by flash chromatography (ethyl acetate/hexanes 1:4) to give the product as a yellow oil (3.9 g).
10 MS (ESI): 340.4 (MH⁺).

Step C]: 1-Phenethyl-3-phenyl-piperidine-2,4-dione

Sodium hydride (1.1 g, 50% in mineral oil) was suspended in ether (40 ml) under argon at RT. 3-(Phenethyl-phenylacetyl-amino)-propionic acid ethyl ester (2.5 g) was added in portions followed by addition of abs. EtOH (0.5 ml). The resulting mixture was
15 refluxed for 2 hours, cooled and poured into water/ice/1 N HCl. The aqueous layer was extracted with ethyl acetate and the organic layer was separated, washed with brine, dried over Na₂SO₄, filtered and evaporated. The residue was purified by flash chromatography (ethyl acetate/hexanes 1:1 and then DCM/MeOH 95:5) to give the desired product as a light yellow foam (801 mg). MS (ESI): 294.4 (MH⁺).

20 Step D]: 1-Phenethyl-3-phenyl-piperidine-2,4-dione 4-oxime

1-Phenethyl-3-phenyl-piperidine-2,4-dione (781 mg), sodium acetate (1.15 g) and hydroxylamine hydrochloride (925 mg) were suspended in EtOH/water 1:1 (25 ml) and the mixture was refluxed for 4 hours. The mixture was then poured into ice/water/1N NaOH and extracted with ethyl acetate. The organic layer was washed with brine, dried
25 and evaporated to give the crude product that was purified by flash chromatography (DCM/MeOH/NH₄OH 98:2:0.25) to give the compound as a white foam (489 mg). MS (ESI): 309.4 (MH⁺).

Step E]: 1-Phenethyl-3-phenyl-piperidine-4-yl amine

1-Phenethyl-3-phenyl-piperidine-2,4-dione 4-oxime (480 mg) was dissolved in
30 abs. ether (30 ml) under argon. LAH (473 mg) was added in one portion and the resulting suspension was refluxed over night. The mixture was carefully poured into 1M aqueous sodium potassium tartrate solution and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried (Na₂SO₄), filtered and evaporated. The residue was purified by flash chromatography (gradient of MeOH in

DCM containing 0.25% NH_4OH and then DCM/MeOH/ NH_4OH 85/15/0.25) to give the compound as the *cis* diastereomer (95 mg) and *trans* diastereomer (101 mg) as colorless oils. MS (ESI): 281.4 (MH^+).

Example 21

5 3-Phenyl-1-benzyl-piperidine-4-yl-amine]

This compound was made according to example 20, Step B] to E] from 3-benzylamino-propionic acid ethyl ester and phenylacetic acid chloride. *Cis* and *trans* diastereomers as yellow oils. MS (ESI): 326.4 (MH^+).

Example 22

10 4-Methyl-1'-phenethyl-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-ylamine

This compound was made according to example 20, Step A] to E] from phenethylamine and ethyl acrylate but with a modified coupling step B] where (4-methyl-pyridin-2-yl)-acetic acid was used instead of the corresponding acid chloride.

Step A] (4-Methyl-pyridin-2-yl)-acetic acid

15 (4-Methyl-pyridin-2-yl)-acetic acid ethyl ester (1.0 g) - prepared according to *Chem. Pharm. Bull.* 32 (12), 1984, 4866-4872 – was dissolved in ethanol (30 ml) and treated with a 1M ethanolic NaOH solution (5.83 ml). The mixture was refluxed for 4 hours, cooled and evaporated *in vacuo*. The residue was dissolved in water (50 ml) and the pH was adjusted to 3.0 with 1M HCl. The solvent was evaporated and the residue was
20 suspended in ethanol (150 ml) and filtered. The clear filtrate was evaporated to dryness and the residue was dried *in vacuo* to give a light yellow solid (1.0 g). NMR ($\text{DMSO}-d_6$): 8.65 (d, 1H); 7.72 (s, 1H), 7.68 (d, 1H), 4.04 (s, 2H), 2.49 (s, 3H).

Step B] 3-{{[2-(4-Methyl-pyridin-2-yl)-acetyl]-phenethyl-amino}-propionic acid ethyl ester:

25 (4-Methyl-pyridin-2-yl)-acetic acid (1.0 g), carbonyldiimidazole (CDI, 1.07 g) and DIPEA (0.856 g) were added to THF (15 ml) and the light brown suspension was allowed to stir at RT for 1 hour. To the mixture was added 3-phenethylamino-propionic acid ethyl ester (0.898 g) dropwise and the resulting mixture was stirred at 55° over night. The mixture was poured into ice/water and the pH was adjusted to 5.0. The mixture was
30 extracted with ethyl acetate and the organic layer was separated, washed with brine, dried over Na_2SO_4 , filtered and evaporated. The residue was purified by flash chromatography

- 36 -

(ethyl acetate/hexanes 2:1) to give the desired product as a light brown liquid (0.462 g). MS (ESI): 355.0 (MH^+).

The final product of this reaction sequence was obtained as a mixture of *cis* and *trans* diastereomers, yellow oil. MS (ESI): 296.4 (MH^+).

5

Example 23**3-(3-Chloro-phenyl)-1-phenethyl-piperidine-4-ylamine**

This compound was made according to example 22 from phenethylamine, ethyl acrylate and (3-chloro-phenyl) acetic acid. The desired compound was obtained as the *cis*-diastereomer as a yellow oil. MS (ESI): 315.1 (MH^+).

10

Example 24**3-(3-Chloro-phenyl)-1-benzyl-piperidine-4-ylamine**

This compound was made according to example 20, steps B] to E] from 3-benzylamino-propionic acid ethyl ester and (3-chloro-phenyl) acetic acid chloride. The desired compound was obtained as a mixture of *cis*- and *trans*-diastereomer as a yellow oil. MS (ESI): 301.2 (MH^+).

15

Example 25**3-(3-Methyl-phenyl)-1-benzyl-piperidine-4-ylamine**

This compound was made according to example 20, steps B] to E] from 3-benzylamino-propionic acid ethyl ester and (3-methyl-phenyl) acetic acid chloride. The desired compound was obtained as a mixture of *cis* and *trans*-diastereomers as a yellow oil. MS (ESI): 281.3 (MH^+).

20

Example 26**3-(3-Chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-ylamine**

This compound was made according to example 20 from ethyl acrylate, 2-(3,4-dimethoxy-phenyl)-ethylamine and (3-chloro-phenyl) acetic acid chloride. The desired compound was obtained as the *cis*-diastereomer as a yellow oil. MS (ESI): 375.2 (MH^+).

25

Example 27

1-Benzyl-3-thiophen-2-yl-piperidine-4-ylamine

This compound was made in analogy to example 20, steps B] to E] from 3-benzylamino-propionic acid ethyl ester and thiophene-2-acetylchloride. The desired
5 compound was obtained as the *trans*-diastereomer as a yellow oil. MS (ESI): 273.2 (MH⁺).

Example 28

3-o-Tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride

Step A]: 1-Benzyl-1-methyl-4-oxo-3-o-tolyl-piperidinium iodide

10 To a solution of 1-benzyl-3-o-tolyl-piperidine-4-one (5165 mg) in acetone (25 ml) was slowly added methyl iodide (3048 mg) at room temperature. The solution was stirred at room temperature over night. A white solid precipitated and was filtered off. The solid was washed four times with 50 ml of acetone and dried under reduced vacuum. The filtrate was evaporated and the residue was stirred with ethyl acetate. The white solid
15 was filtered, washed with ethyl acetate and dried under vacuum. The two solids were combined to yield 1-benzyl-3-butyl-1-methyl-4-oxo-piperidinium iodide as a yellowish solid (4400 mg). MS (ESI): 294.3 (M-I⁻).

Step B]: 3-o-Tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-one

A slurry of 1-benzyl-1-methyl-4-oxo-3-o-tolyl-piperidinium iodide (1000 mg) in
20 water (5 ml) was added in one portion to a refluxing solution of 3,4,5-trimethoxy aniline (395 mg) and anhydrous potassium carbonate (37 mg) in ethanol (10 ml). The reaction was heated to reflux over night. Water was added and the reaction was extracted four times with DCM. The combined organic layers were dried over sodium sulfate, filtered and the solvent was evaporated to leave a red-brown oil, which was purified by flash
25 chromatography (diethyl ether) to give the product as a yellow oil (600 mg). MS (ESI): 356.2 (MH⁺).

Step C]: 3-o-Tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride

3-o-Tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-one (300 mg) was dissolved
30 in ethanol (8 ml). Hydroxylamine hydrochloride (64 mg) and sodium acetate (76 mg) were added. The solution turned from yellow to a brown suspension. After 3 hours stirring at room temperature water (8 ml) was added. A suspension was obtained to

which Al-Ni-alloy (300 mg) was added. 32 % aqueous sodium hydroxide solution (1.4 ml) was added slowly; warming of the reaction mixture was observed. After complete addition, the reaction was stirred for two days at room temperature and the solid was filtered off. The precipitate was washed with DCM. The aqueous solution was extracted
5 with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH/aq. sat MH solution 100:5:1). The separated products were dissolved in ethanol and 1 ml of saturated ethanolic hydrogen chloride solution was added. The solutions were evaporated to yield the *cis*-diastereomer (76 mg), a mixture of
10 *cis*- and *trans*-diastereomers (170 mg) and the *trans*-diastereomer (40 mg) as white solids. MS (ESI): 357.3 (MH⁺).

Example 29

1-(3,4-Dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl amine hydrochloride

Step A]: 1-(3,4-Dimethoxy-phenyl)-piperidine-4-one

15 A slurry of 1-benzyl-1-methyl-4-oxo-piperidinium iodide (9270 mg), 3,4-dimethoxy aniline (3900 mg) and anhydrous potassium carbonate (437 mg) in ethanol (90 ml) / water (45 ml) were heated to reflux for 6 hours. Additional potassium carbonate (200 mg) was added and the reaction was heated to 100 °C over night. Water (50 ml) was added to the reaction mixture, which was extracted three times with DCM.
20 The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered and the solvent was evaporated *in vacuo* to leave the crude product as a dark oil. The residue was purified by column chromatography (ethyl acetate / hexanes = 1:1) to yield the product as a yellow solid (3700 mg). MS (ESI): 236.1 (MH⁺).

Step B]: 1-(3,4-Dimethoxy-phenyl)-3-m-tolyl-piperidine-4-one

25 Palladium acetate (23.8 mg), sodium *tert*-butoxide (306 mg) and 1-(3,4-dimethoxy-phenyl)-piperidine-4-one were dissolved in oxygen free tetrahydrofuran (3 ml) under argon. The mixture was immediately degassed. After addition of 3-bromotoluene (363 mg) and tri(*tert*-butyl)phosphine (25.8 mg) the mixture was stirred at 50°C over night. There was still some starting material left. The reaction was therefore
30 heated to 70°C for 2 hours. After cooling the mixture was diluted with ethyl acetate. It was washed with 1N aqueous hydrochloride solution, water and brine. The organic layer was dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography (hexanes / ethyl acetate = 2:1) to yield the product as a yellow oil (186 mg). MS (ESI): 326.3 (MH⁺).

Step C]: 1-(3,4-Dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl amine hydrochloride

1-(3,4-Dimethoxy-phenyl)-3-m-tolyl-piperidine-4-one (169 mg) was dissolved in ethanol (4 ml). Hydroxylamine hydrochloride (40 mg) and sodium acetate (47 mg) were added. The clear yellow solution turned to a suspension. After 3 hours stirring at room temperature water (4 ml) was added. A suspension was obtained to which Al-Ni-alloy (150 mg) was added. 32 % aqueous sodium hydroxide solution (0.7 ml) was added slowly; warming of the reaction mixture was observed. After complete addition, the reaction was stirred for two days at room temperature and the solid was filtered off. The precipitate was washed with DCM. The aqueous solution was extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and the solvent was evaporated. The residue was purified by flash chromatography (DCM/MeOH/aq. sat NH₃ solution 100:5:1). The separated products were dissolved in ethanol and 1 ml of saturated ethanolic hydrogen chloride solution was added. The solutions were evaporated to yield the *cis*-diastereomer (15 mg), a mixture of the *trans*- and *cis*-diastereomers (144 mg) and the *trans*-diastereomer (6 mg) as white solids. MS (ESI): 327.3 (MH⁺).

Example 30

1-(3,4-Dimethoxy-phenyl)-3-p-tolyl-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 29, steps B] and C] from 1-(3,4-dimethoxy-phenyl)-piperidine-4-one and 4-bromo-toluene to yield a mixture of *cis*- and *trans*-diastereomers as a white solid. In step B] the aryl bromide and tri(tert-butyl)phosphine were added as a solution in tetrahydrofuran and the reaction was run at 70 °C for 5 hours. Separation of the diastereomers (free bases) could not be achieved by flash chromatography. MS (ESI): 327.3 (MH⁺).

Example 31

1-(3,4-Dimethoxy-phenyl)-3-(3,4-dimethyl-phenyl)-piperidine-4-yl amine hydrochloride

The compound was synthesized in analogy to example 30 from 1-(3, 4-dimethoxy-phenyl)-piperidine-4-one and 4-bromo-o-xylene to yield a mixture of *cis*/*trans*-diastereomers as a white solid. Separation of the diastereomers (free bases) could not be achieved by flash chromatography. MS (ESI): 341.3 (MH⁺).

Example 32

1-(3,4-Dimethoxy-phenyl)-3-(3-methoxy-phenyl)-piperidine-4-yl-amine hydrochloride

The compound was synthesized in analogy to example 30 from 1-(3,4-dimethoxy-phenyl)-piperidine-4-one and 4-bromo-anisole to yield a mixture of cis/trans-
5 diastereomers as a white solid. Separation of the diastereomers (free bases) could not be achieved by flash chromatography. MS (ESI): 343.3 (MH⁺).

Example 33

1'-(3,4-Dimethoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-ylamine

The compound was synthesized in analogy to example 30 from 1-(3,4-dimethoxy-phenyl)-piperidine-4-one and 2-bromo-pyridine to yield a mixture of cis/trans-
10 diastereomers as a white solid. Separation of the diastereomers could not be achieved by flash chromatography. MS (ESI): 314.3 (MH⁺).

Example 34

((3R,4S)-4-Amino-1-phenethyl-piperidine-3-yl)-thiazolidin-3-yl-methanone

15 Step A]: (3R,4S)-4-Benzoyloxycarbonylamino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester

(3R,4S)-4-Amino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (540 mg, synthesized according to Duan, Jingwu *et al*, PCT Int. Appl. (2001), WO 2001070673 A2) and WO 2002002525) was dissolved in abs. DCM and NEt₃ (0.39 ml)
20 was added. Benzylchloroformiate (0.33 ml) was added and the mixture was allowed to stir at RT over night. The reaction mixture was poured into ice/brine und the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried and evaporated to give a residue that was purified by flash chromatography (gradient of ethyl acetate in heptane) to give a colorless gum (598 mg). MS (ESI): 393.2 (MH⁺).

25 Step B]: (3R,4S)-4-Methoxycarbonylamino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester

(3R, 4S)-4-Benzoyloxycarbonylamino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (580 mg) was dissolved in THF (20 ml) and a 1 M aqueous solution of LiOH was added (3.0 ml). The mixture was allowed to stir at RT for 20 hours. The
30 solution was poured into ice /brine containing 2 M HCl (2.5 ml). The aqueous layer was extracted with ethyl acetate and the organic layer was separated, washed with brine, dried

(Na₂SO₄) and evaporated. The residue was dried in high vacuum to furnish a colorless foam (558 mg). MS (ESI): 377.3 (MH⁺).

Step C]: (3*R*,4*S*)-4-Benzoyloxycarbonylamino-3-(thiazolidine-3-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester

5 (3*R*,4*S*)-4-Methoxycarbonylamino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester (557 mg) was dissolved in abs. DCM (20 ml). To this solution were added subsequently benzotriazol-1-yloxy)-tripyrrolidinophosphonium-hexafluorophosphate (919 mg), triethylamine (0.47 ml) and – after 5 minutes – thiazolidine (151 mg). The mixture was allowed to stir for 5 hours at RT. The mixture was poured into ice/brine and
10 the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried (Na₂SO₄) and evaporated. The residue was purified by flash chromatography (gradient of ethyl acetate in heptane) to give the product as a white foam (403 mg). MS (ESI): 450.3 (MH⁺).

Step D]: (3*R*,4*S*)-[3-(Thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid
15 benzyl ester

(3*R*, 4*S*)-4-Benzoyloxycarbonylamino-3-(thiazolidine-3-carbonyl)-piperidine-1-carboxylic acid tert-butyl ester (325 mg) was dissolved in abs. DCM (12 ml) and TFA (0.44 ml) was added dropwise. The resulting mixture was then allowed to stir at RT over night and was then evaporated. The residue was transferred into ice/brine, basified to pH
20 10 with 2N NaOH and extracted with ethyl acetate. The organic layer was washed with brine, dried (Na₂SO₄) and evaporated to give a residue that was purified by flash chromatography to give the desired product as a white foam (260 mg). MS (ESI): 350.1 MH⁺.

Step E]: (3*R*- 4*S*)[1-Phenethyl-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-
25 carbamic acid benzyl ester

(3*R*,4*S*)-3-(Thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid benzyl ester (255 mg) was dissolved in DMF (5 ml) and DIPEA (0.28 ml) was added. After 20 minutes, a solution of 2-(bromoethyl)-benzene (169 mg) in DMF (4 ml) was added over a period of 15 minutes. The mixture was stirred at RT over night. The reaction mixture
30 was poured into ice/water/sat. Na₂CO₃ solution and the aqueous layer was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na₂SO₄ and evaporated. The residue was purified by flash chromatography to give the desired product as a light yellow oil (308 mg). MS (ESI): 454.2 (MH⁺).

Step F]: (3*R*,4*S*)-(4-Amino-1-phenethyl-piperidine-3-yl)-thiazolidin-3-yl-methanone

(3*R*,4*S*)-[1-Phenethyl-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid benzyl ester (216 mg) was treated with 33% HBr in acetic acid (2.5 ml) for 2 hours at RT
5 under argon. Ether (15 ml) was added and the resulting suspension was cooled to -10° C and stirred for 1 hour. The solvent was then decanted and the solid washed with a small amount of EtOH. The residue was then dissolved in water (pH was adjusted to 10 with conc. NH₄OH) and the aqueous layer was saturated with NaCl and extracted with ethyl
10 acetate. The organic layer was separated, washed with brine, dried (Na₂SO₄) and evaporated to give a residue that was purified by flash chromatography (gradient of MeOH in DCM containing 0.5% NH₄OH) to furnish the desired product as a light yellow oil (92 mg). MS (ESI): 320.1 MH⁺.

Example 35

((3*S*, 4*R*)-4-Amino-1-phenethyl-piperidine-3-yl)-thiazolidin-3-yl-methanone

15 This material was obtained as described in example 34 from the opposite enantiomer (3*S*, 4*R*)-4-amino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester, thiazolidine and 2-(bromoethyl)-benzene. Yellow oil. MS (ESI): 320.4 (MH⁺).

Example 36

20 [((3*S*, 4*R*)-4-Amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl)-thiazolidin-3-yl-methanone

This material was obtained as described in example 34 from the opposite enantiomer (3*S*, 4*R*)-4-amino-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester, thiazolidine and 2-(2-bromo-ethyl)-pyridine (synthesized according to
25 *Synthesis*, 5, 1987, 452-455). Yellow oil. MS (ESI): 321.4 (MH⁺).

Example 37

1-[(3*S*, 4*R*)-4-Amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone]

This material was obtained according to example 34, but with modified Steps E] and F]:

Step E]: [1-Phenylacetyl-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid methyl ester

3-(Thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid benzyl ester (250 mg) was dissolved in abs. DCM (8 ml) and DIPEA (0.184 ml) was added. The mixture was allowed to stir at -15 °C (ice/salt bath) for 20 min and then phenylacetylchlorid (0.104 ml) was added dropwise. The mixture was warmed to 0 °C and stirred for 30 min. The reaction mixture was poured into ice/water/sat. NaHCO₃ solution and extracted with ethyl acetate. The organic layer was separated, washed with brine, dried over Na₂SO₄ and evaporated *in vacuo*. The residue was purified by flash chromatography to give the desired product [1-phenylacetyl-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid methyl ester (304 mg) as a white foam. MS (ESI): 468.1 (MH⁺).

Step F]: 1-[(3S, 4R)-4-Amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone

The reaction was performed as described in example 34, Step F] from [1-phenylacetyl-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid methyl ester (295 mg) and HBr in HOAc (3 ml) but with a modified purification step: The product was purified by preparative HPLC (RPC18, gradient of CH₃CN in water containing 0.05% formic acid). The appropriate fractions were evaporated to give the desired product as the formic acid salt as a white solid (12 mg). MS (ESI): 334.4 (MH⁺, free base).

Example 38

1-[(3S-4R)-4-Amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-thiophen-2-yl-ethanone

This material was obtained according to example 37 with the appropriate reagents: Colorless gum: MS (ESI): 340.4 (MH⁺, free base).

Example 39

3[(3S,4R) and (3R,4S)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone

Step A]: 4-Amino-1-benzyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester

rac-1-Benzyl-4-oxo-piperidine-3-carboxylic acid methyl ester (25 g) was suspended in 100 ml ammonium hydroxide 25 % and heated at 50 °C during 18 h. The

mixture was cooled with ice and then, NaBH_4 (1 g) was added in several portions. Stirring was continued for 18 h at ambient temperature and the mixture was diluted with water/ice, with cooling, and extracted with AcOEt. The organic extract was washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave a brown oil which was purified by column chromatography (silica gel, heptane/AcOEt, 1/1) and precipitated (AcOEt/heptane) to give 12.1 g (56 %) of the title compound as white solid and 6 g (25 %) of the title compound as its borane salt.

4-Amino-1-benzyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester :

MS: 247.2 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS): 2.28 (t, 2H), 2.46 (t, 2H), 2.99 (s, 2H), 3.49 (s, 3H), 3.53 (s, 2H), 7.22-7.34 (m, 5H), 6.90 and 7.80 (2 s. large, 2H).

4-Amino-1-benzyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester; BH_3 salt:

MS: 247.2 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS) 2.45-2.60 (m, 2H), 2.80-2.90 (m, 1H), 2.92-3.02 (m, 1H), 3.30-3.45 (2d, 2H), 3.53 (s, 3H), 3.80-4.00 (2d, 2H), 7.31-7.40 (m, 5H), 6.90 and 7.80 (2 s. large, 2H).

Step B]: rac-4-Amino-1-benzyl-piperidine-3-carboxylic acid ethyl ester

4-Amino-1-benzyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester BH_3 salt was heated in ethanol with NaOH 25 %. After 72 h at 50 °C the mixture was cooled, washed with water/ice and extracted with AcOEt. The extract was washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave an yellow oil. To a suspension of 4-amino-1-benzyl-1,2,5,6-tetrahydro-pyridine-3-carboxylic acid methyl ester (21 g) in 200 ml THF was added 50 ml TFA at 10 °C under an argon atmosphere. After stirring for 15 min at 0°C, NaBH_4 (6.43 g) was added over a period of 75 min at 10°C. The mixture was stirred for additional 90 min at 0 °C. After adding 100 ml NH_4Cl saturated, the solution was extracted two times with CH_2Cl_2 . The combined extracts were washed with water/ice and brine and dried over sodium sulfate. Evaporation of the solvent gave a yellow oil of the title compound which was taken for the next step without purification

Step C]: (3S,4R) and (3R,4S)-1-Benzyl-4-tert-butoxycarbonylamino-piperidine-3-carboxylic acid ethyl ester and (3S,4S) and (3R,4R)-1-Benzyl-4-tert-butoxycarbonylamino-piperidine-3-carboxylic acid ethyl ester

Rac-4-Amino-1-benzyl-piperidine-3-carboxylic acid ethyl ester (80.7 mMol, 21 g) and BOC_2O (20.5 g) in 200 ml CH_2Cl_2 were stirred 17h at ambient temperature. The solution was evaporated and chromatographed (silica gel, AcOEt/heptane, 1/1) to give

7.05 g of the racemic trans isomer, 1.88 g of the racemic cis isomer and 13.87 g of the racemic mixture of the diastereomers.

(3S,4R) and (3R,4S)-1-Benzyl-4-tert-butoxycarbonylamino-piperidine-3-carboxylic acid ethyl ester:

5 MS: 363.3 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS) 1.11 (t, 3H), 1.36 (s, 9H), 1.65-1.71 (m, 2H), 2.30-2.37 (m, 2H), 2.49-2.55 (m, 1H), 2.63-2.80 (m, 2H), 3.38 (d, 1H), 3.51 (d, 1H), 3.80-3.92 (m, 1H), 4.02 (q, 2H), 6.60 (s large, 1H), 7.21-7.32 (m, 5H).

(3S,4S) and (3R,4R)-1-Benzyl-4-tert-butoxycarbonylamino-piperidine-3-carboxylic acid ethyl ester:

10

MS: 363.3 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS) 1.13 (t, 3H), 1.35 (s, 9H), 1.40-1.50 (m, 1H), 1.62-1.71 (m, 1H), 1.97-2.11 (m, 2H), 2.43-2.50 (m, 2H), 2.74-2.83 (m, 2H), 3.45 (s, 2H), 3.95-4.04 (m, 2H), 6.85 (d, 1H), 7.22-7.33 (m, 5H).

15

Step D]: (3R,4R) and (3S,4S)-4-tert-Butoxycarbonylamino-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester

A suspension of (3S,4S) and (3R,4R)-1-benzyl-4-tert-butoxycarbonylamino-piperidine-3-carboxylic acid ethyl ester (700 mg) and 200 mg of Pd/C (10%) in 10 ml of EtOH and 1 ml of Hunig's base was hydrogenated at 22 °C/1bar overnight. The

20

suspension was filtered, the filtrate evaporated and the residue purified by column chromatography (silica gel, AcOEt) to give a pale yellow solid (538 mg). To a solution of the above product (272 mg) and 3,4-dimethoxybenzeneacetaldehyde (CAS 5703-21-9, 191 mg) in ethanol at 0 °C, was added a solution 8M of pyridine-borane-complex (0.5 ml). After 2 h stirring at 0 °C and 3 h at ambient temperature, the mixture was diluted

25

with water/ice and extracted twice with ethyl acetate. The combined organic layers were washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave an oil which was purified by column chromatography (silica gel, AcOEt) to give 196 mg (45 %) of the title compound as an yellow oil.

MS: 437.4 (M+H)⁺

30

NMR: (DMSO, 1H, 400 MHz, δ , TMS) 1.14-1.23 (m, 3H), 1.36 (s, 9H), 1.40-1.52 (m, 1H), 1.65-1.71 (m, 1H), 2.02 (ddd, 1H), 2.12 (ddd, 1H), 2.42-2.50 (m, 2H), 2.58-2.69 (m, 2H), 2.85 (d, 1H), 2.98 (d, 1H), 3.45-3.57 (m, 1H), 3.62-3.72 (m, 1H), 3.70 (s, 3H), 3.72 (s, 3H), 4.02 (q, 2H), 6.70 (dd, 1H), 6.81-6.86 (m, 3H).

Step E]: (3R,4R) and (3S,4S)-4-Amino-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester

A solution of (3R,4R) and (3S,4S)-4-tert-butoxycarbonylamino-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester (24 mg) in 1 ml TFA
5 was stirred 1 h at 0 °C. The mixture was poured onto NaOH 1M/ ice and extracted with AcOEt. The combined organic layers were washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave an oil which was purified by column chromatography (Isolute SPE Flash NH₂ 10 g, AcOEt/heptane, 1/2) to give 9 mg (50 %) of the title compound.

10 MS: 337.4 (M+H)⁺

Step F]: (3R,4R) and (3S,4S)-4-Amino-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid

(3R,4R) and (3S,4S)-4-Amino-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-carboxylic acid ethyl ester (262 mg) and lithium hydroxide (166 mg) in 5 ml THF, 5 ml
15 MeOH and 1 ml H₂O were stirred for 24 h at ambient temperature. The mixture was diluted with buffer pH 7 and extracted with AcOEt. The combined organic layers were washed with brine and dried over sodium sulfate. Removal of the solvent under reduced pressure gave an oil which was purified by column chromatography (Isolute SPE Flash NH₂, AcOEt) and precipitated (AcOEt/heptane) to give 90 mg (37 %) of the title
20 compound as a white solid.

MS: 309.2 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS) 1.92-2.02 (m, 1H), 2.10-2.20 (m, 1H), 2.75-3.10 (2m, 6H), 3.35-3.48 (m, 2H), 3.55-3.62 (m, 1H), 3.70-3.80 (m, 1H), 3.71 (s, 3H), 3.75 (s, 3H), 6.76 (dd, 1H), 6.85-6.90 (m, 2H), 8.3-8.7 (s.broad, 3H).

25

Example 40

3[(3S,4R) and (3R,4S)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone

Step A]: rac-1-(3, 4-Dimethoxy-phenyl)-4-oxo-piperidine-3-carboxylic acid ethyl ester

30

A mixture of 3,4-dimethoxyaniline (12g), copper (I) chloride (1.7 g), acetic acid (9 ml) and ethyl acrylic acid (26 ml) was heated 17 hours at 140 °C, cooled with ice, diluted with CH₂Cl₂ and washed successively with water, ammonium hydroxide 10%, water and

brine. The organic layers were dried over MgSO_4 , filtered and evaporated. Chromatography (silica gel, AcOEt/heptane, 1/1) delivered a yellow oil (22.8 g) which was dissolved in 50 ml xylene and sodium ethoxide (4.42g) was added. Then, the suspension was stirred 2h at 140 °C, cooled, diluted with AcOEt and washed with water and brine. The aqueous phases were extracted twice with AcOEt, the organic layers were dried over MgSO_4 , filtered, evaporated and chromatographed (silica gel, AcOEt/heptane, 1/3) to obtain the title compound as a white solid (13.53 g, 68 %).

MS: 308.2 (M+H)⁺

Step B]: rac-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid ethyl ester

A suspension of rac-1-(3,4-dimethoxy-phenyl)-4-oxo-piperidine-3-carboxylic acid ethyl ester (640 mg) and ammonium acetate (3g) in 10 ml methanol was stirred 18h at RT., then sodium cyanoborohydride (2g) was added. After 18h at RT, the mixture was diluted with AcOEt, washed twice with water and brine. The organic layers were dried over MgSO_4 , filtered, evaporated and chromatographed (silica gel, AcOEt/heptane, 1/1) to give the title compound (450 mg, 70 %).

Step C]: rac-4-tert-Butoxycarbonylamino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid ethyl ester

A solution of rac-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid ethyl ester (6.47 g) and Boc_2O (5.02g) in 50 ml CH_2Cl_2 was stirred 24 h at RT, then diluted with AcOEt, washed with water and brine. The organic layers were dried over MgSO_4 , filtered, evaporated and chromatographed (silica gel, AcOEt/heptane, 1/1) to leave the title compound as a mixture of *cis*- and *trans*-diastereomers (4.50 g, 53 %).

MS: 409.4 (M+H)⁺

Step D]: rac-4-tert-Butoxycarbonylamino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid

To a solution of rac-4-tert-butoxycarbonylamino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid ethyl ester (170 mg) in 2 ml THF, were added 1 ml NaOH 1M and lithium hydroxide (100 mg). The suspension was stirred 22h at RT., diluted with water and extracted twice with tert-butylmethylether. The aqueous layer was acidified to pH 4, saturated with NaCl and then the product was extracted with 3 portions of AcOEt. The organic layers were dried over MgSO_4 , filtered, evaporated and chromatographed (silica gel, AcOEt) to provide the title compound (38 mg, 55 %).

MS: 381.3 (M+H)⁺

Step E]: [(3S,4R) and (3R,4S)-1-(3,4-Dimethoxy-phenyl)-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid tert-butyl ester and [(3S,4S) and (3R,4R)-1-(3,4-Dimethoxy-phenyl)-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid
5 tert-butyl ester

To a solution of rac-4-tert-butoxycarbonylamino-1-(3,4-dimethoxy-phenyl)-piperidine-3-carboxylic acid (200 mg) in acetonitrile (5 ml) under ice cooling was added Hunig's base (0.5 ml), EDCI (191 mg), HOBT (135 mg) and thiazolidine (0.3 ml). The reaction mixture was stirred 3h at 0 °C and kept at RT for 24h, diluted with AcOEt,
10 washed with 5% NaHCO₃ and brine, dried over magnesium sulfate and concentrated. The crude product was purified by chromatography on silica gel using AcOEt to give [(3S,4R) and (3R,4S)-1-(3,4-dimethoxy-phenyl)-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid tert-butyl ester (73 mg) and [(3S,4S) and (3R,4R)-1-(3,4-dimethoxy-phenyl)-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid tert-butyl ester (81
15 mg).

MS: (M+H)⁺ 452.4.

Step F]:[(3S,4R) and (3R,4S)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone

[(3S,4R) and (3R,4S)-1-(3,4-Dimethoxy-phenyl)-3-(thiazolidine-3-carbonyl)-piperidine-4-yl]-carbamic acid tert-butyl ester (50 mg) was treated with 2 ml TFA for one hour at 0 °C. The reaction mixture was diluted with AcOEt, washed with NaOH 1M and brine, the organic layers were dried over MgSO₄, filtered, evaporated and chromatographed (Isolute Flash SPE NH₂, AcOEt) to give [(3S,4R) and (3R,4S)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone (23
25 mg).

MS: 352.1 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ, TMS, 110°C) 1.70-1.78 (m, 1H), 1.80-1.90 (m, 1H), 2.98-3.04 (m, 3H), 3.12-3.20 (m, 3H), 3.27-3.36 (m, 2H), 3.68 (s, 3H), 3.76 (s, 3H), 3.74-3.80 (m, 2H), 4.55 (d, 2H), 6.42 (dd, 1H), 6.55 (d, 1H), 6.79 (d, 1H).

Example 41

3[(3S,4S) and (3R,4R)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone

This material was obtained from the racemic *trans*-isomer, isolated in example 40, step E, using the same procedure as in example 40, step F, to give 28 mg of the title compound.

MS: 352.1 (M+H)⁺

NMR: (DMSO, 1H, 400 MHz, δ , TMS, 110 °C) 1.40-1.55 (m, 1H), 1.78-1.86 (m, 1H), 2.55-2.90 (m, 4H), 2.90-3.01 (m, 1H), 3.03 (t, 2H), 3.50-3.60 (m, 2H), 3.68 (s, 3H), 3.76 (s, 3H), 3.74-3.90 (2m, 2H), 4.59-4.65 (m, 2H), 6.42 (dd, 1H), 6.56 (d, 1H), 6.79 (d, 1H).

Example 42

3[(3S,4S) and (3R,4R)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone

This material was prepared in analogy to example 40, steps E and F, using 2,5-dihydro-pyrrole.

MS: 332.2 (M+H)⁺

Example 43

3[(3S,4R) and (3R,4S)-4-Amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone

This material was prepared in analogy to example 40, steps E and F, using 2,5-dihydro-pyrrole.

MS: 332.2 (M+H)⁺

Galenical Examples

Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

Ingredients	Per tablet	
Kernel:		
Compound of formula (I)	10.0 mg	200.0 mg
Microcrystalline cellulose	23.5 mg	43.5 mg
Lactose hydrous	60.0 mg	70.0 mg
Povidone K30	12.5 mg	15.0 mg
Sodium starch glycolate	12.5 mg	17.0 mg
Magnesium stearate	1.5 mg	4.5 mg
(Kernel Weight)	120.0 mg	350.0 mg
Film Coat:		
Hydroxypropyl methyl cellulose	3.5 mg	7.0 mg
Polyethylene glycol 6000	0.8 mg	1.6 mg
Talc	1.3 mg	2.6 mg
Iron oxide (yellow)	0.8 mg	1.6 mg
Titanium dioxide	0.8 mg	1.6 mg

5

The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aq. solution / suspension of the above mentioned film coat.

10

Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

Ingredients	Per capsule
Compound of formula (I)	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

- 5 The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:

Ingredients	
Compound of formula (I)	3.0 mg
Polyethylene Glycol 400	150.0 mg
Acetic Acid	q.s. ad pH 5.0
Water for injection solutions	ad 1.0 ml

- 10 The active ingredient is dissolved in a mixture of polyethylene glycol 400 and water for injection (part). The pH is adjusted to 5.0 by acetic acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.

Example D

Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

Ingredients	
Capsule contents	
Compound of formula (I)	5.0 mg
Yellow wax	8.0 mg
Hydrogenated Soya bean oil	8.0 mg
Partially hydrogenated plant oils	34.0 mg
Soya bean oil	110.0 mg
Weight of capsule contents	165.0 mg

Gelatin capsule	
Gelatin	75.0 mg
Glycerol 85 %	32.0 mg
Karion 83	8.0 mg (dry matter)
Titanium dioxide	0.4 mg
Iron oxide yellow	1.1 mg

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.

Example E


Sachets containing the following ingredients can be manufactured in a conventional manner:

Ingredients	
Compound of formula (I)	50.0 mg
Lactose, fine powder	1015.0 mg
Microcrystalline cellulose (AVICEL PH 102)	1400.0 mg
Sodium carboxymethyl cellulose	14.0 mg
Polyvinylpyrrolidone K 30	10.0 mg
Magnesium stearate	10.0 mg
Flavoring additives	1.0 mg

- 5 The active ingredient is mixed with lactose, microcrystalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.

Claims

1. Compounds of the formula I



wherein

5 R^1 is selected from the group consisting of

phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, lower alkoxy, phenyl, phenoxy, halogen, or lower halogenalkyl;

naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

10 tetrahydronaphthyl;

C_{3-7} -cycloalkyl;

$-(CHR^3)_m$ -phenyl, wherein m is 1, 2, or 3 and phenyl being unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy and wherein

15 R^3 is independently selected from hydrogen, lower alkyl or phenyl;

$-(CH_2)_n$ -heteroaryl, wherein n is 1, 2 or 3;

$-(CH_2)_n$ -heteroaryl, wherein n is 1, 2, 3 and heteroaryl is mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

20 $-C(O)-CH_2$ -phenyl, with phenyl being unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

$-C(O)-CH_2$ -heteroaryl; and

- 55 -

-C(O)-CH₂-heteroaryl, wherein heteroaryl is mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

R² is selected from the group consisting of

lower alkyl, lower halogenalkyl;

5 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

10 heteroaryl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

-COOH;

-C(O)-NR⁴R⁵; wherein

15 R⁴ and R⁵ are lower alkyl or together with the nitrogen atom to which they are attached form a 4-, 5- or 6- membered heterocycle which may contain a further heteroatom selected from O, N or S;

and pharmaceutically acceptable salts thereof.

2. Compounds of formula I according to claim 1, wherein R¹ is selected from the group consisting of

20 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

25 -(CHR³)_m-phenyl, wherein m is 1 or 2 and with phenyl being unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy and wherein R³ is hydrogen;

-(CH₂)_n-heteroaryl, wherein n is 1 or 2;

-(CH₂)_n-heteroaryl, wherein n is 1 or 2 and with heteroaryl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy,

5 -C(O)-CH₂-phenyl, with phenyl being unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

-C(O)-CH₂-heteroaryl; and

-C(O)-CH₂-heteroaryl, with heteroaryl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

10 3. Compounds of formula I according to claims 1 or 2, wherein R¹ is selected from the group consisting of

phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy;

15 naphthyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy; and

-(CHR³)_m-phenyl, wherein m is 1 or 2 and with phenyl being unsubstituted or mono-, di-, or trisubstituted by lower alkoxy and wherein R³ is hydrogen.

4. Compounds of formula I according to any of claims 1 to 3, wherein R¹ is

20 phenyl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy.

5. Compounds of formula I according to claims 1 or 2, wherein R¹ is

-(CH₂)_n-heteroaryl, wherein n is 1 or 2; or

25 -(CH₂)_n-heteroaryl, wherein n is 1 or 2 and with heteroaryl mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

6. Compounds of formula I according to claim 1 or 2, wherein R¹ is

-C(O)-CH₂-phenyl, with phenyl being unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, lower alkoxy, phenyl or phenoxy; or

5 -C(O)-CH₂-heteroaryl.

7. Compounds of formula I according to any of claims 1 to 6, wherein R² is selected from the group consisting of

lower alkyl;

10 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy;

heteroaryl, unsubstituted or mono-, di, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy; and

15 -C(O)-NR⁴R⁵, wherein R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 5-membered heterocycle which may contain a further heteroatom selected from O, N or S.

8. Compounds of formula I according to any of claims 1 to 7, wherein R² is n-butyl.

9. Compounds of formula I according to any of claims 1 to 7, wherein R² is

20 phenyl, unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, halogenalkyl, or lower alkoxy.

10. Compounds of formula I according to any of claims 1 to 7, wherein R² is

pyridyl or thienyl, wherein pyridyl and thienyl are unsubstituted or mono-, di-, or trisubstituted, independently, by lower alkyl, halogen, lower halogenalkyl, or lower alkoxy.

25 11. Compounds of formula I according to any of claims 1 to 7, wherein R² is

-C(O)-NR⁴R⁵, wherein R⁴ and R⁵ together with the nitrogen atom to which they are attached form a 5-membered heterocycle which may contain a further heteroatom selected from O, N or S.

12. Compounds of formula I according to claims 1 to 11, selected from

- 5 (cis)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
(trans)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
(cis)-3-butyl-1-benzyl-piperidine-4-yl-amine,
(trans)-3-butyl-1-benzyl-piperidine-4-yl-amine,
(cis)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine,
10 (trans)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-ylamine,
(cis)-3-butyl-1-[2-(3,4-dimethoxy-phenyl-1yl)-ethyl] piperidine-4-ylamine,
(trans)-3-butyl-1-[2-(3,4-dimethoxy-phenyl-1yl)-ethyl] piperidine-4-ylamine,
(cis)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(trans)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
15 (cis)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,
(trans)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,
(cis/trans)-3-butyl-1-(5,6,7,8-tetrahydro-naphthalen-1yl)-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(3,4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
20 (trans)-3-butyl-1-(3,4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-naphthalene-2-yl-piperidine-4-yl-amine hydrochloride,
(trans)-3-butyl-1-naphthalene-2-yl-piperidine-4-yl-amine hydrochloride,
(cis/trans)-3-butyl-1-naphthalene-1-yl-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(3,4-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,

- (*cis*)-3-butyl-1-(4-chloro-3-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
- 5 (*cis*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine
- 10 hydrochloride,
- (*cis/trans*)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-cyclohexyl-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-(3,5-bis-trifluoromethyl-phenyl)-piperidine-4-yl-amine
- 15 hydrochloride,
- (*cis*)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,
- (*trans*)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,
- (*cis/trans*)-3-butyl-1-benzhydryl-4-yl-piperidine-4-yl-amine hydrochloride,
- (*cis*)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,
- 20 (*trans*)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,
- (*cis*)-3-phenyl-1-benzyl-piperidine-4-yl-amine,
- (*trans*)-3-phenyl-1-benzyl-piperidine-4-yl-amine,
- (*cis/trans*)-methyl-1'-phenethyl-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-amine,
- (*cis*)-3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,
- 25 (*cis/trans*)-3-(3-chloro-phenyl)-1-benzyl-piperidine-4-yl-amine,

- (*cis/trans*)-3-(3-methyl-phenyl)-1-benzyl-piperidine-4-yl-amine,
(*cis*)-3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-yl-amine,
(*trans*)-1-benzyl-3-thiophen-2-yl-piperidine-4-yl amine
(*cis*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
5 (*trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-p-tolyl-piperidine-4-yl-amine hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-(3, 4-dimethyl-phenyl)-piperidine-4-yl-amine
10 hydrochloride,
(*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-(3-methoxy-phenyl)-piperidine-4-yl-amine
hydrochloride,
(*cis/trans*)-1'-(3,4-dimethoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-
amine,
15 ((3R,4S)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
[(3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl]-thiazolidin-3-yl-
methanone,
1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone,
20 1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-thiophen-2-yl-
ethanone,
3-[(3S,4R) and (3R,4S)-4-amino-1-[2(3,4-dimethoxy-phenyl)-ethyl]-piperidine-3-
carboxylic acid,
3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-
25 thiazolidine-3-yl-methanone
3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-
dihydropyrrol-1-yl)-3-yl-methanone,

3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone,

and pharmaceutically acceptable salts thereof.

13. Compounds of formula I according to claims 1 to 12, selected from

- 5 (cis)-3-butyl-1-phenethyl-piperidine-4-yl-amine,
(cis)-3-butyl-1-[2-(1H-indol-3-yl)-ethyl]-piperidine-4-yl-amine,
(cis)-3-butyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(4-phenoxy-phenyl)-piperidine-4-yl-amine,
(cis)-3-butyl-1-(3,4-dimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
10 (cis)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
(trans)-3-butyl-1-naphthalen-2-yl-piperidine-4-yl-amine hydrochloride,
(cis/trans)-3-butyl-1-naphthalen-1-yl-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(3,4-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(4-chloro-3-trifluoromethyl-phenyl)-piperidine-4-yl-amine
15 hydrochloride,
(cis)-3-butyl-1-p-tolyl-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
(cis/trans)-3-butyl-1-(3,5-dichloro-phenyl)-piperidine-4-yl-amine hydrochloride,
(cis)-3-butyl-4-methyl-1-phenyl-piperidine-4-yl-amine hydrochloride,
20 (cis)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine
hydrochloride,
(cis/trans)-3-butyl-1-(3-methoxy-5-trifluoromethyl-phenyl)-piperidine-4-yl-amine
hydrochloride,
(cis)-3-butyl-1-(6-methoxy-biphenyl-3-yl)-piperidine-4-yl-amine hydrochloride,
25 (cis)-3-phenyl-1-phenethyl-piperidine-4-yl-amine,

- (*cis/trans*)-methyl-1'-phenethyl-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-amine,
 (*cis*)-3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,
 (*cis/trans*)-3-(3-chloro-phenyl)-1-benzyl-piperidine-4-yl-amine,
 (*cis/trans*)-3-(3-methyl-phenyl)-1-benzyl-piperidine-4-yl-amine,
 5 (*cis*)-3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-yl-amine,
 (*trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
 (*cis/trans*)-3-o-tolyl-1-(3,4,5-trimethoxy-phenyl)-piperidine-4-yl-amine hydrochloride,
 (*cis/trans*)-1-(3,4-dimethoxy-phenyl)-3-m-tolyl-piperidine-4-yl-amine hydrochloride,
 (*cis/trans*)-1'-(3,4-dimethoxy-phenyl)-1',2',3',4',5',6'-hexahydro-[2,3']bipyridinyl-4'-yl-
 10 amine,
 ((3R,4S)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
 ((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,
 [(3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl]-thiazolidine-3-yl-methanone,
 15 1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-phenyl-ethanone,
 1-[(3S,4R)-4-amino-3-(thiazolidine-3-carbonyl)-piperidine-1-yl]-2-thiophen-2-yl-ethanone,
 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone
 20 3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone,
 3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-(2,5-dihydropyrrol-1-yl)-3-yl-methanone,
 and pharmaceutically acceptable salts thereof.

- 25 14. Compounds of formula I according to claims 1 to 13, selected from

(*cis*)-3-(3-chloro-phenyl)-1-phenethyl-piperidine-4-yl-amine,

(*cis/trans*)-3-(3-chloro-phenyl)-1-benzyl-piperidine-4-yl-amine,

(*cis/trans*)-3-(3-chloro-phenyl)-1-[2-(3,4-dimethoxy-phenyl)-ethyl]-piperidine-4-yl-amine,

5 (*cis*)-1-(3,4-dimethoxy-phenyl)-3-*m*-tolyl-piperidine-4-yl-amine hydrochloride,

((3S,4R)-4-amino-1-phenethyl-piperidine-3-yl)-thiazolidine-3-yl-methanone,

((3S,4R)-4-amino-1-(2-pyridin-2-yl-ethyl)-piperidine-3-yl)-thiazolidine-3-yl-methanone,


3-[(3S,4R) and (3R,4S)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-
10 thiazolidine-3-yl-methanone,

3-[(3S,4S) and (3R,4R)-4-amino-1-(3,4-dimethoxy-phenyl)-piperidine-3-yl]-thiazolidin-3-yl-methanone,

and pharmaceutically acceptable salts thereof.

15 15. A process for the manufacture of compounds of formula I according to any of claims 1 to 14, which process comprises either


a) converting a compound of the formula



wherein R¹ and R² are as defined in claim 1,

- 64 -


with hydroxylamine or a salt thereof into an oxime of the formula



wherein R¹ and R² are as defined in claim 1,

and further reducing the oxime of formula III by catalytic hydrogenation or
alternatively by a reduction with a metal hydride into the compound of formula I;
or

b) deprotecting an 4-aminopiperidine derivative of the formula



wherein R¹ and R² are as defined before and R^p is an amino protecting group.

16. Compounds of formula I according to any of claims 1 to 14 when
manufactured by a process according to claim 15.

17. Pharmaceutical compositions comprising a compound according to any of
claims 1 to 14 and a pharmaceutically acceptable carrier and/or adjuvant.

18. Compounds according to any of claims 1 to 14 for use as therapeutic active
substances.

19. Compounds according to any of claims 1 to 14 for use as therapeutic active
substances for the treatment and/or prophylaxis of diseases which are associated with
DPP-IV.

20. Compounds according to any of claims 1 to 14 for use as therapeutic active substances for the treatment and/or prophylaxis of diseases which are associated with DPP-IV such as diabetes, non-insulin dependent diabetes mellitus and / or impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection.

5 21. A method for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, non-insulin dependent diabetes mellitus and / or impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection, which method comprises administering a compound according to any of claims 1 to 14 to a human being or animal.

10 22. The use of compounds according to any of claims 1 to 14 for the treatment and/or prophylaxis of diseases which are associated with DPP-IV.

23. The use according to claim 22 for the treatment and/or prophylaxis of diabetes, non-insulin dependent diabetes mellitus and / or impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection.

15 24. The use of compounds according to any of claims 1 to 14 for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with DPP-IV.

20 25. The use of compounds according to any of claims 1 to 14 for the preparation of medicaments for the treatment and/or prophylaxis of diabetes, non-insulin dependent diabetes mellitus and / or impaired glucose tolerance, obesity, and/or metabolic syndrome or β -cell protection.

26. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.

INTERNATIONAL SEARCH REPORT

tional application No
EP2005/013292

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D211/58 C07D211/60 C07D277/04 A61K31/4468 A61K31/45

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2004/020948 A1 (HARRIS ANTHONY NATHANIEL) 5 February 2004 (2004-02-05) Compounds 1, 3; scheme 1 paragraphs [0105], [0107] -----	1-3,7, 14,15
X	EP 0 092 391 A (KYOWA HAKKO KOGYO CO., LTD) 26 October 1983 (1983-10-26) Formula XIV; reference example 4 page 22, lines 1-32 -----	1-3,7, 14,15
X	US 4 367 232 A (BOIX-IGLEASIAS ET AL) 4 January 1983 (1983-01-04) column 3, lines 31-38; examples 1,3 -----	14
X	EP 0 187 122 A (CIBA-GEIGY AG) 9 July 1986 (1986-07-09) examples 12,13 -----	1,2,5,15
	-/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

25 April 2006

Date of mailing of the international search report

15/05/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Rudolf, M

INTERNATIONAL SEARCH REPORT

International application No

/EP2005/013292

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 252 005 A (CIBA-GEIGY AG) 7 January 1988 (1988-01-07) claim 11; example 34 -----	1,2,5,15
X	RYSZARD LAZNY, ANETA NODZEWSKA, KAROL WOLOSEWICZ: "New Simple Polymeric Supports with Hydrazone Linkers for Solid Phase Synthesis of Ketones and Primary Amines" SYNTHESIS, vol. 2003, no. 18, 2003, pages 2858-2864, XP002378290 Scheme 4; Table 2 line 17 -----	1-3,7,15
P,X	US 2005/209274 A1 (LYNCH JOHN K ET AL) 22 September 2005 (2005-09-22) example 59D -----	1,2,5,15
A	US 6 011 155 A (VILLHAUER ET AL) 4 January 2000 (2000-01-04) column 1, lines 35-46 -----	1-24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP2005/013292

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 20, 21, 22, 25
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 25
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 20-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: 25

Claim 25 does not contain any technical features which would allow a meaningful search be carried out.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

/EP2005/013292

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2004020948	A1	05-02-2004	NONE	
EP 0092391	A	26-10-1983	JP 58180481 A	21-10-1983
US 4367232	A	04-01-1983	CA 1095044 A1	03-02-1981
			DE 2747960 A1	11-05-1978
			ES 463632 A1	16-07-1978
			ES 463633 A1	01-07-1978
			FR 2369263 A1	26-05-1978
			GB 1586468 A	18-03-1981
			JP 53077069 A	08-07-1978
EP 0187122	A	09-07-1986	AU 5178486 A	10-07-1986
			DK 786 A	04-07-1986
			ES 8704896 A1	01-07-1987
			ES 557260 A1	01-10-1987
			ES 557261 A1	01-10-1987
			ES 557262 A1	01-10-1987
			ES 557263 A1	01-10-1987
			FI 855183 A	04-07-1986
			GR 860004 A1	25-04-1986
			HU 40108 A2	28-11-1986
			NO 860007 A	04-07-1986
			PT 81780 A	01-02-1986
EP 0252005	A	07-01-1988	AU 617988 B2	12-12-1991
			AU 8125587 A	18-05-1989
			CA 1322553 C	28-09-1993
			CY 1783 A	20-10-1995
			DD 279674 A5	13-06-1990
			DE 3771280 D1	14-08-1991
			DK 325587 A	27-12-1987
			ES 2044970 T3	16-01-1994
			FI 872807 A	27-12-1987
			GR 3002308 T3	30-12-1992
			HK 134994 A	09-12-1994
			HU 48622 A2	28-06-1989
			IE 59881 B1	20-04-1994
			JP 1970759 C	18-09-1995
			JP 6099420 B	07-12-1994
			JP 63008382 A	14-01-1988
			PT 85157 A	01-07-1987
US 2005209274	A1	22-09-2005	NONE	
US 6011155	A	04-01-2000	US 6124305 A	26-09-2000